Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

ng liver transplant.

"Recurrence of HCV infection among liver transplant patients is universal and immediate.  Clinicians have long sought ways to prevent re-infection by HCV, improve transplant patient outcomes and extend survival," said Dr. Mutimer.  "The potential of ITX-5061 to prevent or reduce viral infection of the new liver by halting viral-entry into healthy cells represents an extraordinarily novel approach, and we are excited to advance the clinical development of this promising antiviral compound."

The Phase 1b trial of ITX-5061 in liver transplant recipients is funded through an educational grant from iTherX with the National Institute of Health Research Biomedical Research Unit (NIH-BRU Birmingham).

This is a second clinical study for ITX-5061 in hepatitis C. The first study, a single agent placebo-controlled dose response study commenced in August 2010, is being conducted in treatment naïve chronic HCV patients by the AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Diseases.

About Hepatitis CHepatitis C virus (HCV) infection, a disease that attacks the liver, affects 170 million people worldwide.   The majority of individuals develop chronic infection and up to 20 percent of infected individuals will develop cirrhosis with the attendant risks of liver failure and liver cell cancer.  The current standard of care is combination antiviral treatment with pegylated interferon-alpha and ribavirin, which results in a cure for approximately half of all patients.  Unfortunately, many patients present with clinically silent infection or advanced disease, at which time antiviral treatment is generally ineffective.  For these patients, liver transplantation may be the only option.  End-stage liver disease due to chronic HCV infection has become the leading indication for liver transplantation in the United States. Recurrence of hepatitis C virus after liver trans
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigalâ„¢ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)...   West Pharmaceutical Services, Inc. (NYSE: ... for injectable drug administration, announced today it plans to ... site in Waterford, Ireland . The ... cartridges and other high-value packaging components, in order to ... operational, this new site could bring approximately 150 new ...
(Date:10/1/2014)... Oct. 1, 2014 The Cardinal ... Interested parties can learn about the company,s ... is supporting the health care continuum by ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... and the chief executive officer,s letter to ...
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3
... , SAN DIEGO, Nov. 25 NuVasive, Inc. (Nasdaq: ... for minimally disruptive surgical treatments for the spine, announced today that ... at 5:30 p.m. ET / 2:30 p.m. PT. The conference ... Company,s products and will include comments from management followed by a ...
... ... a new market research report is available in its ... Trends & Analysis http://www.reportlinker.com/p0164267/Intranasal-Drug-Delivery---US-Market-Trends--Analysis.html , The ... of therapeutic applications from the delivery of conventional local ...
Cached Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... technologies, testing methods, and processes to improve medical decontamination efforts. ... in other industries, and is using that knowledge to help improve ... ... Midbrook, Inc., a Jackson, MI based manufacturer of medical decontamination ...
... SAN ANTONIO, May 12 Eye Care Centers of ... acquired $65,360,000 of ECCA,s 10-3/4 percent Senior Subordinated Notes ... managed and/or advised by DDJ Capital Management, LLC were ... amount, plus accrued interest to the purchase date. The ...
... a meeting today with President Obama and business leaders, ... drew praise for their innovative employee health care and ... the meeting, President Obama referred to the participants, which ... President and CEO Steven Burd, as "some of the ...
... today,s release of the annual Social Security and ... two largest programs are on a troubled fiscal ... together on reforms of both programs aimed at ... to recognize the underlying structural factors contributing to ...
... Minn. -- Mayo Clinic and Grameen Healthcare are ... leveraging Mayo Clinic,s knowledge and expertise in health ... models. A multi-disciplinary team from Mayo Clinic has ... where it was agreed that following an initial ...
... FARMINGDALE, N.Y., May 12 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has announced their attendance and participation in ... held in Los Angeles, CA, March 19-21, 2009. ...
Cached Medicine News:Health News:Midbrook Developing Decontamination Standards for Medical Industry 2Health News:Midbrook Developing Decontamination Standards for Medical Industry 3Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Mayo Clinic and Grameen Healthcare join forces to launch demonstration project 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
... the ISI Lexan Universal K ... table for lower and upper ... and neck, and lower extremity ... package gives you the ability ...
... Our manufacturing process ... flux-density nanocrystals ensuring magnetic ... allied with the rigid ... no magnetic aggregation occurs ...
Medicine Products: